Sector Expert: Joseph Gomes
Noble Capital Markets
Joe Gomes is a senior research analyst at Noble Capital Markets. Gomes has over 20 years experience as a generalist analyst covering the small-to-mid cap space. Before joining the company, he was senior equity analyst for Wm. Smith & Co. His prior equity research experience includes stints at Oppenheimer & Co., McGinn Smith & Co., where he spearheaded the development of an institutional research effort, C.L. King & Co., Federal Filings, and 13D Research. Gomes is a Chartered Financial Analyst and holds an MBA in Finance from Pace University and a BS in Agricultural Economics from Cornell University.
Streetwise Reports
Companies Commented On
- Avivagen Inc.
- Stem Holdings Inc. dba Driven By Stem
Recent Quotes
"STEM entered into a letter of intent to acquire Colorado Harvest Co."
—
Joseph Gomes, Noble Capital Markets
(10/27/21)
more >
"VIV signed an agreement to supply 6.3 tons of OxC-beta to a customer."
—
Joseph Gomes, Noble Capital Markets
(10/19/21)
more >
"STEM launched the Budee Cannabis Delivery app in Apple's App Store."
—
Joseph Gomes, Noble Capital Markets
(10/13/21)
more >
"VIV entered an eight-year distribution agreement with AB Vista."
—
Joseph Gomes, Noble Capital Markets
(10/7/21)
more >
"VIV's pipeline continues to expand."
—
Joseph Gomes, Noble Capital Markets
(9/30/21)
more >
"STEM received a license to open a distribution hub in Mendota, Calif."
—
Joseph Gomes, Noble Capital Markets
(9/21/21)
more >
"STEM acquired a cannabis extraction company and two dispensaries."
—
Joseph Gomes, Noble Capital Markets
(9/21/21)
more >
"STEM continued to build momentum during Q3 FY21."
—
Joseph Gomes, Noble Capital Markets
(8/18/21)
more >
"Momentum continues to build for VIV."
—
Joseph Gomes, Noble Capital Markets
(6/4/21)
more >
"STEM's Q2 FY21 gross revenue was $12.4M, net revenue was $10.5M."
—
Joseph Gomes, Noble Capital Markets
(5/24/21)
more >
"STEM's expansion is positive and in line with company growth plans."
—
Joseph Gomes, Noble Capital Markets
(5/5/21)
more >
"We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."
—
Joseph Gomes, Noble Capital Markets
(5/4/21)
more >
"VIV received a purchase order for 4.4 mt of OxC-beta Livestock."
—
Joseph Gomes, Noble Capital Markets
(4/26/21)
more >
"Another manuscript on benefits of VIV's OxC-beta will be published."
—
Joseph Gomes, Noble Capital Markets
(3/5/21)
more >
"We are initiating research coverage on VIV with an Outperform rating."
—
Joseph Gomes, Noble Capital Markets
(3/1/21)
more >
